SERS Platform for Integrated Enrichment, Isolation, and Identification of Multiple Respiratory Viruses in a Single...

Influenza (flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar clinical symptoms, complicating the diagnosis and clinical management of these critical respiratory infections. Thus, there is an urgent need for rapid on-site detection technologies that can simultaneously detect SARS-CoV-2 and influenza A viruses. Here, we have developed the first platform that combines in situ sampling with immune swabs and multichannel surface-enhanced Raman spectroscopy (SERS) for simultaneous screening of these two respiratory viruses in a single assay. A seed-mediated growth method was used to assemble a number of silver spheres on the surface of Fe₃O₄@SiO₂ spheres, which not only creates extensive Raman hotspots but also provides numerous sites for Raman signaling molecules, enhancing the sensing sensitivity. Integrating two specific Raman signaling molecules into the nanospheres allows for the parallel detection of both viruses, improving the efficiency of SERS signal read-out. Rapid quantitative screening of both SARS-CoV-2 and H1N1 is achievable within 15 min, with detection limits of 7.76, and 8.13 pg·mL^-1 for their respective target proteins. The platform demonstrated excellent performance in testing and analyzing 98 clinical samples (SARS-CoV-2:50; influenza A:48), achieving sensitivities of 88.00, and 95.83% for SARS-CoV-2 and influenza A, respectively. Pearson's correlation analysis revealed a significant correlation with the clinical CT values (P < 0.0001), underscoring the great potential of this platform for the early, rapid, and simultaneous diagnostic discrimination of multiple pathogens.